ACAD
37.32
+0.53
+1.4409%
AEMD
6.4
+0.1
+1.59%
APRI
0.333
-0.015
-4.2241%
ARNA
1.69
+0.02
+1.20%
ATEC
0.38
+0.01
+2.70%
CNAT
2.36
+0.03
+1.29%
CRXM
0.175
-0.004
-2.235%
CYTX
2
-0.01
-0.50%
DXCM
87.76
-0.56
-0.63%
GNMK
10.08
+0.11
+1.10%
HALO
9.73
+0.21
+2.2069%
ILMN
157.47
+7.37
+4.91%
INNV
0.58
-0.02
-3.33%
INO
9.635
+0.085
+0.8921%
ISCO
1.93
-0.07
-3.50%
ISIS
57.56
0.00
0.00%
LGND
134.81
+0.56
+0.42%
LPTN
1.96
-0.01
-0.5025%
MBVX
0.62
-0.02
-3.12%
MEIP
1.4
+0.01
+0.72%
MNOV
6.08
-0.17
-2.72%
MRTX
4.82
+0.12
+2.55%
MSTX
0.36
+0.01
+2.8857%
NBIX
49.48
-0.14
-0.28%
NUVA
61.12
-0.88
-1.42%
ONCS
1.75
0.00
0.00%
ONVO
4.222
+0.022
+0.524%
OREX
3.28
+0.01
+0.31%
OTIC
14.65
+0.19
+1.31%
QDEL
20.93
+0.08
+0.38%
RCPT
231.96
0.00
0.00%
RGLS
3.86
+0.34
+9.6563%
RMD
64.87
-1.08
-1.64%
SPHS
5.25
-0.39
-6.9220%
SRNE
6.22
+0.01
+0.16%
TROV
5.4
+0.07
+1.31%
VICL
4.21
+0.02
+0.48%
VOLC
18
0.00
0.00%
ZGNX
9.07
+0.12
+1.34%
ACAD
37.32
+0.53
+1.4409%
AEMD
6.4
+0.1
+1.59%
APRI
0.333
-0.015
-4.2241%
ARNA
1.69
+0.02
+1.20%
ATEC
0.38
+0.01
+2.70%
CNAT
2.36
+0.03
+1.29%
CRXM
0.175
-0.004
-2.235%
CYTX
2
-0.01
-0.50%
DXCM
87.76
-0.56
-0.63%
GNMK
10.08
+0.11
+1.10%
HALO
9.73
+0.21
+2.2069%
ILMN
157.47
+7.37
+4.91%
INNV
0.58
-0.02
-3.33%
INO
9.635
+0.085
+0.8921%
ISCO
1.93
-0.07
-3.50%
ISIS
57.56
0.00
0.00%
LGND
134.81
+0.56
+0.42%
LPTN
1.96
-0.01
-0.5025%
MBVX
0.62
-0.02
-3.12%
MEIP
1.4
+0.01
+0.72%
MNOV
6.08
-0.17
-2.72%
MRTX
4.82
+0.12
+2.55%
MSTX
0.36
+0.01
+2.8857%
NBIX
49.48
-0.14
-0.28%
NUVA
61.12
-0.88
-1.42%
ONCS
1.75
0.00
0.00%
ONVO
4.222
+0.022
+0.524%
OREX
3.28
+0.01
+0.31%
OTIC
14.65
+0.19
+1.31%
QDEL
20.93
+0.08
+0.38%
RCPT
231.96
0.00
0.00%
RGLS
3.86
+0.34
+9.6563%
RMD
64.87
-1.08
-1.64%
SPHS
5.25
-0.39
-6.9220%
SRNE
6.22
+0.01
+0.16%
TROV
5.4
+0.07
+1.31%
VICL
4.21
+0.02
+0.48%
VOLC
18
0.00
0.00%
ZGNX
9.07
+0.12
+1.34%
Home » Archive by Category

Syndication

Epilepsy Drugs Market Size To Reach $5.47 Billion By 2024: Grand View Research, Inc.

July 25, 2016 – 4:30 am

SAN FRANCISCO, July 25, 2016 /PRNewswire/ — The global epilepsy drugs market is expected to reach over USD 5,474.14 million by 2024, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness training to the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Access full research report: http://www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market 

Key Findings:

  • The second generation anti-epileptic drug class is estimated to have over 30% market share in 2015 owing to the high prescription rates, improved tolerability, and increased efficacy due to the novel mechanisms of action of these drugs
  • The third generation anti-epileptic drug class is expected to witness the fastest growth with a CAGR of over 4% over the forecast period. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • The growing need to improve the efficacy of the existent drugs and the need to develop new and enhanced anti-epileptic drugs to minimize the associated side-effects, such as dizziness, fatigue, weight gain, and depression are the propelling factors expected to drive the market growth over the forecast period.
  • North America dominated the market in terms of revenue with over USD 2,000 million in 2015 owing to the presence of well-established healthcare infrastructure, favorable government initiatives directed at the betterment of the healthcare system, and the presence of extensive research and development activities

Market Segmentation:

  • Global Epilepsy Drug market (Revenue, USD Million, 2013 – 2024)

    • First generation anti-epileptic drug
    • Second generation anti-epileptic drug
    • Third generation anti-epileptic drug
  • Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2013 – 2024)
    • North America

      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
    • Asia Pacific
      • India
      • China
    • Latin America
      • Brazil
    • MEA
      • South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: www.grandviewresearch.com 

Logo – http://photos.prnewswire.com/prnh/20160524/371361LOGO

 

SOURCE Grand View Research, Inc.

Epilepsy Drugs Market Size To Reach $5.47 Billion By 2024: Grand View Research, Inc.

July 25, 2016 – 4:30 am

SAN FRANCISCO, July 25, 2016 /PRNewswire/ — The global epilepsy drugs market is expected to reach over USD 5,474.14 million by 2024, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness training to the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Access full research report: http://www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market 

Key Findings:

  • The second generation anti-epileptic drug class is estimated to have over 30% market share in 2015 owing to the high prescription rates, improved tolerability, and increased efficacy due to the novel mechanisms of action of these drugs
  • The third generation anti-epileptic drug class is expected to witness the fastest growth with a CAGR of over 4% over the forecast period. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • The growing need to improve the efficacy of the existent drugs and the need to develop new and enhanced anti-epileptic drugs to minimize the associated side-effects, such as dizziness, fatigue, weight gain, and depression are the propelling factors expected to drive the market growth over the forecast period.
  • North America dominated the market in terms of revenue with over USD 2,000 million in 2015 owing to the presence of well-established healthcare infrastructure, favorable government initiatives directed at the betterment of the healthcare system, and the presence of extensive research and development activities

Market Segmentation:

  • Global Epilepsy Drug market (Revenue, USD Million, 2013 – 2024)

    • First generation anti-epileptic drug
    • Second generation anti-epileptic drug
    • Third generation anti-epileptic drug
  • Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2013 – 2024)
    • North America

      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
    • Asia Pacific
      • India
      • China
    • Latin America
      • Brazil
    • MEA
      • South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: www.grandviewresearch.com 

Logo – http://photos.prnewswire.com/prnh/20160524/371361LOGO

 

SOURCE Grand View Research, Inc.

Sr. Cost Accountant – Ajinomoto Althea, Inc. – San Diego, CA

July 24, 2016 – 4:28 pm

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…
From Ajinomoto Althea, Inc. – 24 Jul 2016 23:28:20 GMT
– View all San…

Part Time Lab Assistant – Ajinomoto Althea, Inc. – San Diego, CA

July 24, 2016 – 4:28 pm

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…
From Ajinomoto Althea, Inc. – 24 Jul 2016 23:28:20 GMT
– View all San…

Sr. Cost Accountant – Ajinomoto Althea, Inc. – San Diego, CA

July 24, 2016 – 4:28 pm

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…From Ajinomoto Althea, Inc. – Sun, 24 Jul 2016 23:28:20 GMT – View all San Diego jobs

Part Time Lab Assistant – Ajinomoto Althea, Inc. – San Diego, CA

July 24, 2016 – 4:28 pm

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…From Ajinomoto Althea, Inc. – Sun, 24 Jul 2016 23:28:20 GMT – View all San Diego jobs

Pipette Calibration Specialist (San Diego)

July 24, 2016 – 2:22 pm

Eppendorf North America
Job Description
Incumbent:
Job Title: Pipette Calibration Specialist
Department: Calibration Services
Reports To: Supervisor, Calibration Services, West
FLSA Status: Non-Exempt
Prepared Date: 2016
QUALIFICATIONS: To pe […

Sales Executive- 5106 – TalentZok – San Diego, CA

July 24, 2016 – 1:50 pm

Attention to detail, even when multi-tasking or when under a deadline. 2+ years of sales experience in a fast paced, deadline driven environment….
From Indeed – 24 Jul 2016 20:50:25 GMT
– View all San Diego jobs

Sales Executive- 5106 – TalentZok – San Diego, CA

July 24, 2016 – 1:50 pm

Attention to detail, even when multi-tasking or when under a deadline. 2+ years of sales experience in a fast paced, deadline driven environment….From Indeed – Sun, 24 Jul 2016 20:50:25 GMT – View all San Diego jobs

Proofreader – Lab Support – San Diego, CA

July 23, 2016 – 7:17 am

Our client, a global leader in the Biotech space, is seeking a qualified Bioinformatics Engineer to join their rapidly expanding team!…
From Lab Support – 23 Jul 2016 14:17:58 GMT
– View all San Diego jobs